You are on page 1of 2

Federal Register / Vol. 71, No.

194 / Friday, October 6, 2006 / Notices 59125

Name of Committee: Center for Scientific Contact Person: Zhiqiang Zou, MD, PhD, DEPARTMENT OF HEALTH AND
Review Special Emphasis Panel, T Cell/B Scientific Review Administrator, Center for HUMAN SERVICES
Cell Mechanisms. Scientific Review, National Institutes of
Date: October 17, 2006. Health, 6701 Rockledge Drive, Room 6190, National Institutes of Health
Time: 1 p.m. to 2:30 p.m. MSC 7804, Bethesda, MD 20892, 301–451–
Agenda: To review and evaluate grant Center for Scientific Review; Amended
0132, zouzhiq@csr.nih.gov.
applications.
Place: National Institutes of Health, 6701 Name of Committee: Center for Scientific Notice of Meeting
Rockledge Drive, Bethesda, MD 20892, Review Special Emphasis Panel, NIDDK PAR Notice is hereby given of a change in
(Telephone Conference Call). 06 113. the meeting of the Drug Discovery and
Contact Person: Calbert A. Laing, PhD, Date: October 31–November 1, 2006.
Scientific Review Administrator, Center for
Molecular Pharmacology Study Section,
Time: 8 a.m. to 5 p.m.
Scientific Review, National Institutes of October 5, 2006, 8 a.m. to October 6,
Agenda: To review and evaluate grant
Health, 6701 Rockledge Drive, Room 4210, 2006, 5 p.m., Wyndham City Center
applications.
MSC 7812, Bethesda, MD 20892, 301–435– Hotel, 1143 New Hampshire Ave., NW.,
Place: National Institutes of Health, 6701
1221, laingc@csr.nih.gov.
Rockledge Drive, Bethesda, MD 20892,
Washington, DC 20037 which was
This notice is being published less than 15 published in the Federal Register on
days prior to the meeting due to the timing (Virtual Meeting).
Contact Person: Daniel F. McDonald, PhD, September 15, 2006, 71 FR 54511–
limitations imposed by the review and 54512.
funding cycle. Scientific Review Administrator, Chief, Renal
and Urological Sciences IRG, Center for The meeting will be held at the Red
Name of Committee: Center for Scientific Lion Hotel on Fifth Avenue, 1415 Fifth
Review Special Emphasis Panel, Cognition Scientific Review, National Institutes of
and Perception SRA Conflict Review. Health, 6701 Rockledge Drive, Room 4214, Avenue, Seattle, WA 98101. The
Date: October 27, 2006. MSC 7814, Bethesda, MD 20892, (301) 435– meeting dates and time remain the
Time: 8:30 a.m. to 10:30 a.m. 1215, mcdonald@csr.nih.gov. same. The meeting is closed to the
Agenda: To review and evaluate grant Name of Committee: Center for Scientific public.
applications. Review Special Emphasis Panel, Molecular, Dated: September 28, 2006.
Place: Hotel Helix, 1430 Rhode Island
Cellular and Developmental Neurobiological Anna Snouffer,
Ave., NW., Washington, DC 20005.
Contact Person: Dana Jeffrey Plude, PhD, Small Business Applications. Acting Director, Office of Federal Advisory
Scientific Review Administrator, Center for Date: October 31, 2006. Committee Policy.
Scientific Review, National Institutes of Time: 8:30 a.m. to 5 p.m. [FR Doc. 06–8517 Filed 10–5–06; 8:45 am]
Health, 6701 Rockledge Drive, Room 3192, Agenda: To review and evaluate grant
BILLING CODE 4140–01–M
MSC 7848, Bethesda, MD 20892, 301–435– applications.
2309, pluded@csr.nih.gov. Place: Jurys Washington Hotel, 1500 New
Name of Committee: Center for Scientific Hampshire Avenue, NW., Washington, DC DEPARTMENT OF HEALTH AND
Review Special Emphasis Panel, Non-HIV 20036. HUMAN SERVICES
Microbial Vaccine Development. Contact Person: Michael A. Lang, PhD,
Date: October 30, 2006. Scientific Review Administrator, Center for National Institutes of Health
Time: 8 a.m. to 5 p.m. Scientific Review, National Institutes of
Agenda: To review and evaluate grant Health, 6701 Rockledge Drive, Room 4140, Prospective Grant of an Exclusive
applications. MSC 7850, Bethesda, MD 20892, (301) 435– License: Development and
Place: The Watergate, 2650 Virginia 1265, langm@csr.nih.gov.
Avenue, NW., Washington, DC 20037. Commercialization of Therapeutic
Contact Person: Jin Huang, PhD, Scientific Name of Committee: Center for Scientific Products for Autoimmune Diseases
Review Administrator, Center for Scientific Review Special Emphasis Panel, Member Including Rheumatoid Arthritis (RA),
Review, National Institutes of Health, 6701 Conflicts in Biobehavioral Regulation and Inflammatory Bowel Disease (IBD) and
Rockledge Drive, Room 4095G, MSC 7812, Learning. Psoriasis
Bethesda, MD 20892, 301–435–1187, Date: October 31, 2006.
jh377p@nih.gov. Time: 12 p.m. to 2 p.m. AGENCY: National Institutes of Health,
Name of Committee: Center for Scientific Agenda: To review and evaluate grant Public Health Service, HHS.
Review Special Emphasis Panel, Radiation applications. ACTION: Notice.
Therapy and Biology SBIR/STTR. Place: National Institutes of Health, 6701
Date: October 30–31, 2006. Rockledge Drive, Bethesda, MD 20892, SUMMARY: This notice, in accordance
Time: 8:30 a.m. to 5 p.m. (Telephone Conference Call). with 35 U.S.C. 209(c)(1) and 37 CFR
Agenda: To review and evaluate grant Contact Person: Jane A. Doussard- 404.7(a)(1)(i), announces that the
applications. Roosevelt, PhD, Scientific Review Department of Health and Human
Place: National Institutes of Health, 6701 Services is contemplating the grant of an
Administrator, Center for Scientific Review,
Rockledge Drive, Bethesda, MD 20892, exclusive license to practice the
National Institutes of Health, 6701 Rockledge
(Virtual Meeting).
Drive, Room 3184, MSC 7848, Bethesda, MD inventions embodied in United States
Contact Person: Bo Hong, PhD, Scientific
Review Administrator, Center for Scientific 20892, (301) 435–4445, doussarj@csr.nih.gov. Patent Application Number 60/181,909
Review, National Institutes of Health, 6701 entitled ‘‘Identification of a Novel
(Catalogue of Federal Domestic Assistance Domain in the Tumor Necrosis Factor
Rockledge Drive, Room 6194, MSC 7804,
Program Nos. 93.306, Comparative Medicine;
Bethesda, MD 20892, 301–435–5879, Receptor Family that Mediates Pre-
hongb@csr.nih.gov. 93.333, Clinical Research, 93.306, 93.333,
ligand Receptor Assembly and
93.337, 93.393–93.396, 93.837–93.844,
Name of Committee: Center for Scientific Function’’ filed February 11, 2000 (HHS
93.846–93.878, 93.892,93.893, National
Review Special Emphasis Panel, ZRG1 ONC– Ref. No. E–095–2000/0–US–01); U.S.
P (03): Cancer Chemoprevention. Institutes of Health, HHS)
Patent Application No. PCT/US01/
cprice-sewell on PROD1PC66 with NOTICES

Date: October 30, 2006. Dated: September 28, 2006.


04125 entitled ‘‘Identification of a Novel
Time: 4 p.m. to 6 p.m. Anna Snouffer,
Agenda: To review and evaluate grant
Domain in the Tumor Necrosis Factor
Acting Director, Office of Federal Advisory Receptor Family that Mediates Pre-
applications.
Committee Policy. ligand Receptor Assembly and
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892, [FR Doc. 06–8516 Filed 10–5–06; 8:45 am] Function’’ filed February 9, 2001, 2000
(Telephone Conference Call). BILLING CODE 4140–01–M (HHS Ref. No. E–095–2000/0–PCT–02);

VerDate Aug<31>2005 14:52 Oct 05, 2006 Jkt 211001 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 E:\FR\FM\06OCN1.SGM 06OCN1
59126 Federal Register / Vol. 71, No. 194 / Friday, October 6, 2006 / Notices

U.S. Patent Application No. 10/203,495, Rockville, MD. 20852–3804; Telephone: DEPARTMENT OF HEALTH AND
filed August 9, 2002, entitled (301) 435–2950; Facsimile: (301) 402– HUMAN SERVICES
‘‘Identification of Novel Domain in the 0220; E-mail: BAHARM@OD.NIH.GOV.
Tumor Necrosis Factor Receptor Family National Institutes of Health
that Mediates Pre-ligand Receptor SUPPLEMENTARY INFORMATION: The
Assembly and Function’’ (E–095–2000/ invention relates to methods and Fogarty International Center (FIC)
0–US–03); U.S. Patent Application No. compositions that are useful for novel 2007–2011 Strategic Plan
60/694,015 entitled ‘‘Amelioration of treatment of arthritis and other
autoimmune diseases. This technology AGENCY: John E. Fogarty International
Inflammatory Arthritis Targeting the Center (FIC), National Institutes of
Pre-ligand Assembly Domain (PLAD) of discloses the identification of a
Health. (NIH), Department of Health and
Tumor Necrosis Factor Receptors’’ filed functional domain, Pre-ligand Assembly
Human Services (DHHS).
June 24, 2005 [E–095–2000/2–US–01]; Domain (PLAD), an essential part in
U.S. Patent Application No. 60/717,589 signaling involving receptors of the ACTION: Notice with request for
entitled ‘‘Amelioration of Inflammatory Tumor Necrosis Factor superfamily and comments.
Arthritis Targeting the Pre-ligand its use in ameliorating rheumatoid SUMMARY: The FIC is initiating a
Assembly Domain (PLAD) of Tumor arthritis (RA). PLAD is essential for
Necrosis Factor Receptors’’ filed strategic planning process to culminate
signaling involving TFNR including in the FIC Strategic Plan 2007–2011. To
September 16, 2005 [E–095–2000/3– TNFR–1 (p60), TNFR–2 (p80), Fas,
US–01]; U.S. PCT Application entitled anticipate and set priorities for global
TRAIL–R, LTR, CD40, CD30, CD27, health research and research training,
‘‘A Potential Novel Therapeutic Protein HVEM, OX40 and DR4 and can be
Molecule of Inflammatory Arthritis FIC requests input from scientists, the
isolated as functional polypeptides general public, and interested parties.
Targeting the Pre-ligand Assembly which can be useful in inhibiting the
Domain (PLAD) of Tumor Necrosis The goal of this strategic planning
first step in TNFR mediated signaling, process is to identify current and future
Factor Receptor Type 1’’ filed February
ligand-independent assembly of needs and directions for global health
9, 2001 [E–095–2000/4–PCT–01];
European Patent Application No. members of the TNFR superfamily. The research. The existing FIC strategic plan
01910476.9 entitled ‘‘Identification of ability to inhibit TNFR signaling can be viewed at http://www.fic/
Novel Domain in the Tumor Necrosis suggests that these PLAD polypeptides nih.gov/about/plan/StrategicPlan.pdf.
Factor Receptor Family that Mediates may be useful in development of new DATES: In order to ensure full
Pre-ligand Receptor Assembly and therapeutic molecules or as therapeutic consideration, responses must be
Function’’ filed February 9, 2001 [E– molecules themselves used for submitted by November 15, 2006.
095–2000/0–EP–06]; Australian Patent modulation of immune responses, ADDRESSES: Interested persons and
Application No. 2001238076 entitled apoptosis, and inflammation. The organizations should submit their
‘‘Identification of Novel Domain in the inventors have discovered compounds responses to Strategic Plan, Fogarty
Tumor Necrosis Factor Receptor Family that interfere with PLAD and can block International Center, National Institutes
that Mediates Pre-ligand Receptor the effects of TNF–a. of Health, 16 Center Drive, Building 16,
Assembly and Function’’ issued on The prospective exclusive license will MSC 6705, Bethesda, MD 20892–6705,
February 9, 2001 [E–095–2000/0–AU– be royalty-bearing and will comply with telephone 301–594–7857, Fax 301–496–
04]; and Canadian Patent Application the terms and conditions of 35 U.S.C. 8496, E-mail: FICStratPlan@nih.gov.
No. 2399388 entitled ‘‘Identification of 209 and 37 CFR 404.7. The prospective Comments may be submitted
Novel Domain in the Tumor Necrosis exclusive license may be granted unless electronically via the Strategic Planning
Factor Receptor Family that Mediates Web site located at http://
within sixty (60) days from the date of
Pre-ligand Receptor Assembly and nihfictest.cit.nih.gov/StratPlan/
this published notice, the NIH receives
Function’’ filed February 9, 2001, [E– index.htm. Comments may also be
095–2000/0–CA–05] to Domantis, Inc. written evidence and argument that
submitted by mail or fax to the address
The prospective exclusive license establish that the grant of the license
above.
territory may be worldwide and the would not be consistent with the
requirements of 35 U.S.C. 209 and 37 SUPPLEMENTARY INFORMATION:
field of use may be limited to
therapeutic applications for CFR 404.7. Background
autoimmune diseases including Applications for a license in the field The Fogarty International Center (FIC)
rheumatoid arthritis (RA) inflammatory of use filed in response to this notice works to enhance global health by
bowel disease (IBD) and psoriasis as will be treated as objections to the grant promoting and supporting health
covered under the agreement and based of the contemplated exclusive license. research and research training
upon the Patent Rights. Comments and objections submitted to worldwide. The Center uses a variety of
DATES: Only written comments and/or this notice will not be made available international research and research
license applications which are received for public inspection and, to the extent training grants and fellowships to build
by the National Institutes of Health on permitted by law, will not be released research capacity and human capital in
or before December 5, 2006 will be under the Freedom of Information Act, developing countries and foster
considered. 5 U.S.C. 552. partnerships between U.S. scientists and
ADDRESSES: Requests for copies of the their foreign counterparts. The FIC is
Dated: September 28, 2006.
patent and/or patent applications, currently developing a new strategic
Steven M. Ferguson, plan to guide Center activities for the
inquiries, comments and other materials
cprice-sewell on PROD1PC66 with NOTICES

relating to the contemplated exclusive Director, Division of Technology Development next 5 years mindful of the need to set
license should be directed to: Mojdeh and Transfer, Office of Technology Transfer, research and research training priorities.
Bahar, J.D., M.A., Technology Licensing National Institutes of Health. We welcome outside participation in
Specialist, Office of Technology [FR Doc. E6–16526 Filed 10–5–06; 8:45 am] the process.
Transfer, National Institutes of Health, BILLING CODE 4140–01–P Request for Comments: To ensure the
6011 Executive Boulevard, Suite 325, continued relevance of its Strategic

VerDate Aug<31>2005 14:52 Oct 05, 2006 Jkt 211001 PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 E:\FR\FM\06OCN1.SGM 06OCN1